World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 October 2017
Main ID:  NCT01557322
Date of registration: 08/02/2012
Prospective Registration: No
Primary sponsor: Pfizer
Public title: Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)
Scientific title: Evaluation of the Clinical Characteristics, Real-world Treatment Pathways, and Outcomes of Patients With Moderate Rheumatoid Arthritis
Date of first enrolment: October 2011
Target sample size: 1754
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT01557322
Study type:  Observational
Study design:   
Phase:  N/A
Countries of recruitment
Contacts
Name:     Pfizer CT.gov Call Center
Address: 
Telephone:
Email:
Affiliation:  Pfizer
Key inclusion & exclusion criteria

Inclusion Criteria:

The Test Group will be patients with rheumatoid arthritis, newly starting therapy with
etanercept (Enbrel). Inclusion criteria for the exposed cohort subjects are:

- Patients aged 18 years and over at the time of diagnosis;

- Patients from the BSRBR with moderate RA as defined by a DAS28 (>3.2 and =5.1);

- Patients who have given informed consent for long term follow-up and access to all
medical records;

- Patients initiating (i.e. at leats one treatment) treatment with etanercept (Enbrel)
for RA.

The Control Group:

- Patients aged 18 years and over a the time of diagnosis;

- Patients from the BSRBR with moderate RA as defined by a DAS28 (>3.2 and =5.1);

- Patients who have given informed consent for long term follow-up and access to all
medical records; Patients are receiving at least one traditional DMARD and have never
been prescribed a biologic agent;

Exclusion Criteria:

Per BSRBR registry since data is retropsectively being analyzed



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis
Intervention(s)
Biological: etanercept
Drug: methotrexate (MTX)
Primary Outcome(s)
Change From Baseline in Tender Joints Count (TJC) at Month 60 [Time Frame: Baseline, Month 60]
Number of Participants With American College of Rheumatology (ACR) Criteria [Time Frame: Baseline]
Body Mass Index (BMI) [Time Frame: Baseline]
Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Month 60 [Time Frame: Baseline, Month 60]
Change From Baseline in Swollen Joints Count (SJC) at Month 60 [Time Frame: Baseline, Month 60]
Direct and Indirect Cost of Rheumatoid Arthritis (RA) Treatment [Time Frame: Baseline]
Number of Participants With Previous and Current Disease Modifying Anti-Rheumatic Drugs (DMARDs) [Time Frame: Baseline]
Change From Baseline in C-Reactive Protein (CRP) Level at Month 60 [Time Frame: Baseline, Month 60]
Change From Baseline in Disease Activity Score Based on 28-joints Count (DAS28) at Month 60 [Time Frame: Baseline, Month 60]
Change From Baseline in Patient's Global Assessment (PtGA) of Disease Activity at Month 60 [Time Frame: Baseline, Month 60]
Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 60 [Time Frame: Month 60]
Duration of Disease (Rheumatoid Arthritis) [Time Frame: Baseline]
Number of Participants With Chest X-Ray Prior to New Therapy [Time Frame: Baseline]
Number of Participants With Systemic Features [Time Frame: Baseline]
Time to Disease Worsening [Time Frame: Baseline up to Month 60]
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Month 60 [Time Frame: Baseline, Month 60]
Blood Pressure (BP) [Time Frame: Baseline]
Number of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 60 [Time Frame: Month 60]
Change From Baseline in Euro Quality of Life - 5 Dimensions (EQ-5D) at Month 60 [Time Frame: Baseline, Month 60]
Number of Participants With Prior Joint Replacement or Surgery [Time Frame: Baseline]
Time Since First Rheumatologist Visit [Time Frame: Baseline]
Number of Participants With Comorbidities [Time Frame: Baseline]
Time Since Recalled Symptom Onset [Time Frame: Baseline]
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Month 60 [Time Frame: Baseline, Month 60]
Time to Therapeutic Goal [Time Frame: Baseline up to Month 60]
Change From Baseline in Pain Visual Analog Scale (VAS) Score at Month 60 [Time Frame: Baseline, Month 60]
Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 60 [Time Frame: Month 60]
Number of Rheumatoid Arthritis (RA) Related Visits [Time Frame: Baseline]
Secondary Outcome(s)
Secondary ID(s)
B1801345
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 31/10/2013
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT01557322
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey